Truist Financial’s 4D Molecular Therapeutics FDMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$358K Hold
25,000
– – ﹤0.01% 2407
2026
Q2
$332K Hold
25,000
– – ﹤0.01% 2473
2026
Q1
$233K Hold
25,000
– – ﹤0.01% 2559
2025
Q4
$188K Buy
+25,000
New +$254K ﹤0.01% 2624

Other funds holding FDMT

Truist Financial's FDMT Position: Q3 2026 in Review

Truist Financial held its 4D Molecular Therapeutics (FDMT) position steady in Q3 2026 at 25,000 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #2407.

Truist Financial first reported a position in FDMT in Q4 2025 and has held it in 4 quarters since. 167 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Truist Financial held 25,000 shares of 4D Molecular Therapeutics worth $358K as of Q3 2026.
  • Truist Financial left its 4D Molecular Therapeutics share count unchanged in Q3 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q3 2026, its #2407 holding.
  • Truist Financial first reported a position in 4D Molecular Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 167 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Truist Financial's 13F filing for Q3 2026, filed 30 Oct 2026.